Insider Trading Alert - ROSE, ITMN And MHFI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, June 9, 2014, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $201.24 to $22,465,418.44.

Highlighted Stocks Traded by Insiders:

Rosetta Resources (ROSE) - FREE Research Report

Craddock James E, who is Chairman, CEO & President at Rosetta Resources, sold 3,000 shares at $49.36 on June 9, 2014. Following this transaction, the Chairman, CEO & President owned 123,705 shares meaning that the stake was reduced by 2.37% with the 3,000-share transaction.

The shares most recently traded at $50.80, up $1.44, or 2.83% since the insider transaction. Historical insider transactions for Rosetta Resources go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 3,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 6,000
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 15,000

The average volume for Rosetta Resources has been 1.1 million shares per day over the past 30 days. Rosetta Resources has a market cap of $3.0 billion and is part of the basic materials sector and energy industry. Shares are up 6.16% year-to-date as of the close of trading on Monday.

Rosetta Resources Inc., an independent exploration and production company, is engaged in the acquisition and development of onshore energy resources in the United States. The company has a P/E ratio of 16.4. Currently, there are 8 analysts who rate Rosetta Resources a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ROSE - FREE

TheStreet Quant Ratings rates Rosetta Resources as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Rosetta Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

InterMune (ITMN) - FREE Research Report

Hodgman John, who is EVP, Finance & CFO at InterMune, sold 921 shares at $39.66 on June 9, 2014. Following this transaction, the EVP, Finance & CFO owned 23,567 shares meaning that the stake was reduced by 3.76% with the 921-share transaction.

Leff Jonathan A, who is EVP, Research & Development at InterMune, sold 190 shares at $39.66 on June 9, 2014. Following this transaction, the EVP, Research & Development owned 46,131 shares meaning that the stake was reduced by 0.41% with the 190-share transaction.

The shares most recently traded at $41.14, up $1.48, or 3.6% since the insider transaction. Historical insider transactions for InterMune go as follows:

  • 4-Week # shares sold: 21,094
  • 12-Week # shares sold: 34,717
  • 24-Week # shares sold: 297,742

The average volume for InterMune has been 2.6 million shares per day over the past 30 days. InterMune has a market cap of $4.1 billion and is part of the health care sector and drugs industry. Shares are up 182.89% year-to-date as of the close of trading on Monday.

InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. Currently, there are 9 analysts who rate InterMune a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITMN - FREE

TheStreet Quant Ratings rates InterMune as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow. Get the full InterMune Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

McGraw Hill Financial (MHFI) - FREE Research Report

Vittor Kenneth M, who is EVP & General Counsel at McGraw Hill Financial, sold 15,000 shares at $84.05 on June 9, 2014. Following this transaction, the EVP & General Counsel owned 100,322 shares meaning that the stake was reduced by 13.01% with the 15,000-share transaction.

The shares most recently traded at $84.06, up $0.01, or 0.01% since the insider transaction. Historical insider transactions for McGraw Hill Financial go as follows:

  • 4-Week # shares sold: 12,974
  • 12-Week # shares sold: 12,974
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 30,886

The average volume for McGraw Hill Financial has been 1.5 million shares per day over the past 30 days. McGraw Hill Financial has a market cap of $22.8 billion and is part of the services sector and diversified services industry. Shares are up 7.71% year-to-date as of the close of trading on Monday.

McGraw Hill Financial, Inc., a financial intelligence company, provides credit ratings, benchmarks, and analytics to capital and commodity markets worldwide. The stock currently has a dividend yield of 1.43%. The company has a P/E ratio of 25.8. Currently, there are 8 analysts who rate McGraw Hill Financial a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MHFI - FREE

TheStreet Quant Ratings rates McGraw Hill Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full McGraw Hill Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

Amazon's Big Weakness in the Supreme Court Sales Tax Ruling

Amazon's Big Weakness in the Supreme Court Sales Tax Ruling

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Tesla's Automotive Gross Margins May Be Overstated, Analysts Suggest

Tesla's Automotive Gross Margins May Be Overstated, Analysts Suggest

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices